ÃÖ¼ºÇý ¸íÀÇ

Ä¡¸Å, ÀÎÁöÀå¾Ö, ³ë¼èÀÇ ¿¹¹æ°ú Ä¡·á ¿¬±¸ÀÇ ¼±µµÀÚ

ÃÖ¼ºÇý ¸íÀÇ

  • ¼Ò ¼Ó
    ÀÎÇÏ´ëÇб³ Àǰú´ëÇÐ ºÎ¼Óº´¿ø ½Å°æ°ú
  • Àü¹®ºÐ¾ß
    Ä¡¸Å, ÀÎÁöÀå¾Ö, µÎÅë, ¾îÁö·³, ³ëÈ­, ³úÀüÁõ (°£Áú) Áúȯ, ¼ö¸éÁúȯ

¼­¿ï´ëÇб³ Àǰú´ëÇÐÀ» Á¹¾÷ÇØ ÇöÀç ÀÎÇÏ´ëÇб³ Àǰú´ëÇÐ ½Å°æ°ú ±³¼ö·Î ÀçÁ÷ ÁßÀÌ´Ù. ¼Ò¼Ó º´¿ø¿¡¼­´Â Áø·á¿Í ÇÔ²² ÀÓ»ó½ÃÇè¼¾ÅÍÀåÀ» ¸Ã°í ÀÖ´Ù.
´ë¿ÜȰµ¿À¸·Î ´ëÇÑÄ¡¸ÅÇÐȸ ÀÌ»çÀåÁ÷À» ¼öÇàÇϰí ÀÖÀ¸¸ç, ÀÎÁöÁßÀçÄ¡·áÇÐȸ ÀÌ»çÀåµµ ¿ªÀÓÇÑ ¹Ù ÀÖ´Ù. ÁÖ¿ä Áø·á ºÐ¾ß´Â Ä¡¸Å¿Í ÀÎÁöÀå¾ÖÀ̰í, ¿¬±¸ ¹× Çмú Ȱµ¿À¸·Î º¤Æí ÀÌ»óÀÇ ³í¹®À» ±¹³»¿Ü¿¡ ¹ßÇ¥Çß´Ù. °æµµÀÎÁöÀå¾Ö¿Í Ä¡¸Å ȯÀÚ ´ë»óÀÇ ÀÎÁöÁßÀçÄ¡·áÀÇ ½ÅÀÇ·á±â¼ú ÀÎÁõÀ» ȹµæÇßÀ¸¸ç Ä¡¸Å¿¹¹æÇÁ·Î±×·¥ÀÎ ½´ÆÛºê·¹ÀÎ ÇÁ·Î±×·¥ÀÇ °³¹ß µî ȯÀÚµéÀÇ Ä¡¸Å ¿¹¹æ, Á¶±â Áø´Ü ¹× Ä¡·á¸¦ À§ÇØ Èû¾²°í ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¼­¿ï´ëÇб³ ÀÇÇаú Çлç
  • ¼­¿ï´ëÇб³ ¿¹¹æÀÇÇÐ ¼®»ç
  • ¼­¿ï´ëÇб³ ¿¹¹æÀÇÇÐ ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ÇöÀçÀÎÇϴ뺴¿ø ½Å°æ°ú ±³¼ö
  • úÞ) ÀÎÇϴ뺴¿ø ÀÓ»ó½ÃÇè¼¾ÅÍÀå
  • ¹Ì±¹ÇÇÃ÷¹ö±×´ëÇк´¿ø ½Å°æ°ú, research scholar (2006 ~ 2007)
  • »ï¼º¼­¿ïº´¿ø ½Å°æ°ú Àӻ󿬱¸ÀÇ (1998 ~ 1999)
  • ¼­¿ï´ëº´¿ø ½Å°æ°ú Àü°øÀÇ (1994 ~ 1998)

ÇÐȸȰµ¿

Academic activities
  • 2024.04 ~ 2026.04´ëÇÑÄ¡¸ÅÇÐȸ ÀÌ»çÀå
  • 2022.01 ~ 2023.12ÀÎÁöÁßÀçÄ¡·áÇÐȸ ÀÌ»çÀå
  • 2024.01 ~ 2025.12ÀÎÁöÁßÀçÄ¡·áÇÐȸ °í¹®
  • 2016.01 ~ 2021.12´ëÇѽŰæ°úÇÐȸ ±³À°ÀÌ»ç
½´ÆÛºê·¹ÀÎ ÀÎÁöÁßÀçÄ¡·á ÇÁ·Î±×·¥
´ëÇ¥¼­Àû

½´ÆÛºê·¹ÀÎ ÀÎÁöÁßÀçÄ¡·á ÇÁ·Î±×·¥

  • ÀúÀÚ(±Û)³ªÇظ®, Á¤ÁöÇâ, ÃÖ¼ºÇý, ¹®¼Ò¿µ, ¹ÚÀ¯°æ, ȫâÇü
  • ÃâÆÇ»çÇÐÁö»ç
  • ¹ßÇàÀÏ2020-04-14
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 4°Ç
Á¦ ¸ñ ½Å°æ½É¸®ÀçȰ°ú Ä¡¸ÅȯÀÚ
ÃâÆÇ»ç ÇÐÁö»ç ¹ßÇàÀÏ 2019³â
Á¦ ¸ñ CogMCI Àç°¡Çü ÀÎÁöÁßÀçÄ¡·áÇÁ·Î±×·¥
ÃâÆÇ»ç ÇÐÁö»ç ¹ßÇàÀÏ 2017³â
Á¦ ¸ñ µÎ³ú¿ª·®°­È­
ÃâÆÇ»ç ¹ü¹®»ç ¹ßÇàÀÏ 2024³â
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face-to-face and video communication platforms in mild cognitive impairment (SUPERBRAIN-MEET): A randomized controlled trial
¹ßÇ¥³âµµ 2025(In press) ¹ßÇ¥Áö Alzheimer's & Dementia
Á¦ ¸ñ Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Dement Neurocogn Disord
Á¦ ¸ñ Effects of the multidomain intervention with nutritional supplements on cognition and gut microbiome in early symptomatic Alzheimer's disease: a randomized controlled tria
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Alzheimers Dement (Amst)
Á¦ ¸ñ Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Front Aging Neurosci
Á¦ ¸ñ Functional brain changes using electroencephalography after a 24-week multidomain intervention program to prevent dementia
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Front Aging Neurosci
Á¦ ¸ñ Impact of a multidomain lifestyle intervention on regional spontaneous brain activity
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Front Aging Neurosci
Á¦ ¸ñ Serum neurofilament light chain level as a predictor of cognitive stage transition
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Alzheimers Res Ther

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

°æµµÀÎÁöÀå¾Ö ´ë»ó ÀÎÁöÁßÀçÄ¡·á ÇÁ·Î±×·¥ÀÎ CogMCIÇÁ·Î±×·¥À» °³¹ßÇÏ°í °æµµÀÎÁöÀå¾Ö¿Í Ä¡¸Å ȯÀÚ ´ë»ó ÀÎÁöÁßÀçÄ¡·áÀÇ ½ÅÀÇ·á±â¼ú ÀÎÁõÀ» ¹ÞÀ½.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

°æµµÀÎÁöÀå¾Ö¿Í Ãʱâ Ä¡¸Å ´ë»óÀÇ ÀÎÁö ÀúÇÏ Áö¿¬À» À§ÇÑ ´ÙÁß¿µ¿ªÁßÀç ÇÁ·Î±×·¥ÀÎ ½´ÆÛºê·¹ÀÎ ÇÁ·Î±×·¥À» °³¹ßÇÔ.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

Áúº´ÀÇ Ä¡·á¸¦ À§Çؼ­´Â ȯÀںеéÀÇ ³ë·ÂÀÌ Áß¿äÇÕ´Ï´Ù. ¾àµµ Á¤¼º½º·´°Ô Àß Ã¬°Ü¼­ µå¼Å¾ßÇϰí¿ä.
Áúº´¿¡ ³ª»Û »ýȰ ½À°üÀº ²÷°í ÁÁÀº »ýȰ½À°üÀ» ½ÇõÇÏ´Â ¿©·¯ºÐµéÀÇ ³ë·ÂÀÌ µ¿¹ÝµÉ ¶§ ³î¶ó¿î °á°ú°¡ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

ÀÎÇÏ´ëÇб³ Àǰú´ëÇÐ ºÎ¼Óº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
032-890-2000
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

ÇÑÁø±×·ì ͺ Á¶ÁßÈÆ ȸÀåÀÇ '±â¾÷ÀÌÀÍÀÇ »çȸȯ¿ø°ú Áö¿ª»çȸ º¸Àº'À̶ó´Â ¼þ°íÇÑ ¶æ¿¡ µû¶ó 1996³â °³¿øÇÑ ÀÎõ ÃÖÃÊÀÇ ´ëÇк´¿øÀ¸·Î¼­ ÀÎõ ÀÇ·áü°èÀÇ ÇÙ½É ¿ªÇÒÀ» ¼öÇàÇϸç, ´ëÇѹα¹ ÀÇ·á ¹ßÀü¿¡ ±â¿©ÇØ ¿Ô½À´Ï´Ù. ȯÀÚ°æÇèÆò°¡ Àü±¹ 1À§, ÀÀ±ÞÀÇ·á±â°üÆò°¡ Àü±¹ 1À§, ÀÇ·áÁúÆò°¡ 1-°¡ µî±Þ µî ±¹³» ÃÖ»óÀ§±ÇÀÇ ÀÇ·á¼­ºñ½º ¼öÁØÀ» º¸À¯ÇÑ º´¿øÀ¸·Î ÀÎÁ¤ ¹Þ½À´Ï´Ù.

ÀÎÇÏ´ëÇб³ Àǰú´ëÇÐ ºÎ¼Óº´¿ø		 À̹ÌÁö

ÀÎõ±¤¿ª½Ã Áß±¸ ÀÎÇ×·Î 27 (½ÅÈﵿ 3°¡ 7- 206)

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä